EZH2 is a sensitive marker of malignancy in salivary gland tumors

Diagn Pathol. 2015 Sep 17:10:163. doi: 10.1186/s13000-015-0392-z.

Abstract

Background: The immunohistochemical detection of Enhancer of zeste homologue 2 (EZH2) proved to be a useful tool to recognize the malignant nature of tumors in a wide variety of neoplasms. The histological diagnostics of salivary gland tumors is a challenging task, and a reliable marker of malignancy would be extremely helpful.

Methods: EZH2 expression was investigated in 54 malignant and 40 benign salivary gland tumors of various histological types by standard immunohistochemistry.

Results: The majority (n = 52) of the malignant tumors stained positively, while all the investigated benign tumors were negative for EZH2.

Conclusions: EZH2 expression in salivary gland tumors, similarly to the tumors of other organs is not characteristic for any tumor type, but is a solid marker of the malignant nature of the tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma / pathology*
  • Biomarkers, Tumor / analysis*
  • Carcinoma / metabolism
  • Carcinoma / pathology*
  • Enhancer of Zeste Homolog 2 Protein
  • Humans
  • Immunohistochemistry
  • Polycomb Repressive Complex 2 / analysis
  • Polycomb Repressive Complex 2 / biosynthesis*
  • Salivary Gland Neoplasms / metabolism
  • Salivary Gland Neoplasms / pathology*

Substances

  • Biomarkers, Tumor
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Polycomb Repressive Complex 2